BFFAF
BASF SE
OTC Markets OTCQXUSDEQUITY
Basic Materials
DELAYED
Last price
59.13
■ 0.00 (0.00%)
MARKET · —
Price
Open
59.13
Prev close
59.13
Day high
57.00
Day low
57.00
Volume
877
Market cap
$50.91B
P/E (TTM)
21.35
52W range
47.11 – 64.86
Trailing performance
Returnvs SPY
1W
+1.95%
+3.3%
1M
+6.75%
+3.0%
3M
-2.68%
-5.8%
6M
+4.05%
-7.0%
YTD
+13.52%
+1.2%
1Y
+6.39%
-13.6%
3Y
+21.12%
-53.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$50.91B
Enterprise value$71.15B
Revenue (TTM)$61.59B
Gross profit$14.50B
EBITDA$6.57B
Net income$2.09B
EPS (TTM)$2.77
Free cash flow$1.05B
Total cash$7.89B
Total debt$26.68B
Book value / share$48.89
Shares outstanding860.92M
Float866.07M
Short % of float—
Dividend yield4.46%
Beta (5Y)0.75
Valuation & profitability ratios
Trailing P/E21.35
Forward P/E—
PEG ratio0.66
Price / sales—
Price / book1.21
EV / revenue1.16
EV / EBITDA10.83
Gross margin23.55%
Operating margin5.18%
Profit margin9.42%
Return on equity6.12%
Return on assets2.33%
Debt / equity71.36
Current ratio1.86
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $59.66B | $65.26B | $68.90B | $87.33B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.62B | $1.30B | $225.00M | -$627.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.62B | $1.30B | $225.00M | -$627.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $15.75B | +3.4% |
| Next quarter | — | — | $14.83B | +5.7% |
| Current year | — | — | $63.34B | +6.2% |
| Next year | — | — | $64.42B | +1.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions39.15%
Institutions holding552
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Moving averages & technicals
SMA 10
58.79
+0.58% from price
SMA 20
58.11
+1.75% from price
SMA 50
55.94
+5.70% from price
SMA 100
58.52
+1.03% from price
SMA 200
55.87
+5.83% from price
EMA 12
58.57
+0.96% from price
EMA 26
57.72
+2.45% from price
EMA 50
57.26
+3.26% from price
RSI (14)
62.3
Neutral
MACD (12,26,9)
0.85
Hist 0.02
ATR (14)
0.49
0.83% of price
Realised vol 30D
33.8%
Annualised
Bollinger upper
60.59
20, 2σ
Bollinger lower
55.64
20, 2σ
50 / 200 cross
Golden
55.94 vs 55.87
Trend bias
Above 200
+5.83%
Risk profile
Beta vs SPY
0.34
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
33.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.3%
Peak to trough
Max drawdown 5Y
-51.4%
Peak to trough
ATR 14
0.49
0.83% of price
Beta (reported)
0.75
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
BASFY Opens Global SAP and Diaper Performance Lab in Mumbai
Zacks · 2d ago
Is BASF (XTRA:BAS) Undervalued After FDA Approval Of Its Tinosorb S UV Filter?
Simply Wall St. · 4d ago
Medical Plastics Market to Reach USD 48.77 billion by 2031, Growing at a CAGR of 7.0% — MarketsandMarkets™
GlobeNewswire · 4d ago
Microbial Inoculants & N-Fixing Microbes Market Report 2026–2035: Evaluating $6.7 Billion Forecast, Liquid Formulations, and Strategies of Novonesis, BASF, Corteva, and Bioceres
GlobeNewswire · 8d ago
Following UPM Biochemicals' Commercial Launch at Europe's Largest Biorefinery in Leuna, New Study Maps Growth Trajectory for Bio-Based Bisphenol Replacements
GlobeNewswire · 9d ago
Foam Packaging Market Report 2025–2034: Evaluating $33.8 Billion Projection, PE & PU Rigid Foams, and Market Shares of UFP Tech, Zotefoams, Sealed Air, and BASF
GlobeNewswire · 9d ago
Following Evonik's 24% Q2 EBITDA Surge and Raised 2026 Outlook, New Report Outlines Trajectory for Sustainable Polymeric Surfactants
GlobeNewswire · 10d ago
Private 5G Network Deployment Tracker & Forecasts 2026-2030 | Covers 9,300 Engagements Across 130 Countries
GlobeNewswire · 10d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.